@article{AMJ3835,
author = {Akira Iyoda},
title = {A result of prospective biomarker trial on excision repair cross complementing group 1 (ERCC1) in advanced non-small-cell lung cancer: ERCC1 trial},
journal = {AME Medical Journal},
volume = {2},
number = {5},
year = {2017},
keywords = {},
abstract = {Chemotherapies with platinum doublet have an important role in managing lung cancers in spite of progress on epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) or anaplastic lymphoma kinase (ALK)-inhibitor. However, we cannot customize current cytotoxic chemotherapies to heighten an effect of treatment and prevent adverse drug reactions because there are no available biomarkers in practice. Development of biomarkers to predict a survival benefit for platinum-based chemotherapy is of importance in treatment for patients with lung cancer. Excision repair cross complementing group 1 (ERCC1) is one of the most promising
biomarker (1), which proteins play an essential role in nucleotide excision repair (2).},
issn = {2520-0518}, url = {https://amj.amegroups.org/article/view/3835}
}